FATAL OUTCOMES FROM DRUG INTERACTIONS: INSIGHTS FROM THE FDA ADVERSE EVENT REPORTING SYSTEM

被引：0
|
作者：
Gomez-Lumbreras, A. [1 ]
Villa, Zapata L. [2 ]
Malone, D. [1 ]
机构：
[1] Univ Utah, Dept Pharmacotherapy, Coll Pharm, Salt Lake City, UT USA
[2] Univ Georgia, Coll Pharm, Atlanta, GA USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EPH103
引用
收藏
页码：S172 / S172
页数：1
相关论文
共 50 条
  • [21] Fatal reports in intramuscular vs oral antipsychotics in the FDA adverse event reporting system (AERS)
    Sorsaburu, Sebastian
    Chilcott, Karen E.
    DeLisle, F. Patrick
    Hornbuckle, Kenneth
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2006, 15 : S222 - S222
  • [22] Navigating the complex landscape of benzodiazepine- and Z-drug diversity: insights from comprehensive FDA adverse event reporting system analysis and beyond
    Koniuszewski, Filip
    Vogel, Florian D. D.
    Dajic, Irena
    Seidel, Thomas
    Kunze, Markus
    Willeit, Matthaeus
    Ernst, Margot
    [J]. FRONTIERS IN PSYCHIATRY, 2023, 14
  • [23] Serious adverse events with tedizolid and linezolid: pharmacovigilance insights through the FDA adverse event reporting system
    Gatti, Milo
    Fusaroli, Michele
    Raschi, Emanuel
    Moretti, Ugo
    Poluzzi, Elisabetta
    De Ponti, Fabrizio
    [J]. EXPERT OPINION ON DRUG SAFETY, 2021, 20 (11) : 1421 - 1431
  • [24] Drug-induced liver injury associated with antiseizure medications from the FDA Adverse Event Reporting System (FAERS)
    Kamitaki, Brad K.
    Minacapelli, Carlos D.
    Zhang, Pengfei
    Wachuku, Christopher
    Gupta, Kapil
    Catalano, Carolyn
    Rustgi, Vinod
    [J]. EPILEPSY & BEHAVIOR, 2021, 117
  • [25] Potentially Fatal Adverse Allergic Events to Intravenous Thrombolytics: An Analysis from Adverse Event Reporting System
    Khan, Asif
    Zarar, Amna
    Adil, Malik
    Qureshi, Adnan
    [J]. NEUROLOGY, 2013, 80
  • [26] Potentially Fatal Adverse Allergic Events to Intravenous Thrombolytics: An analysis from Adverse Event Reporting System
    Khan, Asif A.
    Zarar, Amna
    Adil, Malik M.
    Qureshi, Adnan I.
    [J]. STROKE, 2013, 44 (02)
  • [27] An evaluation of the FDA adverse event reporting system and the potential for reporting bias
    Monnot, Andrew D.
    Fung, Ernest S.
    Compoginis, Goli S.
    Towle, Kevin M.
    [J]. JOURNAL OF COSMETIC DERMATOLOGY, 2021, 20 (06) : 1849 - 1854
  • [28] Drug-Induced Insomnia: Descriptive analysis of FDA Adverse Event Reporting System
    Ahmed, Nehad J.
    Khan, Mohd F.
    [J]. ASIAN JOURNAL OF PHARMACEUTICS, 2022, 16 (03) : 357 - 360
  • [29] Metformin adverse event profile: a pharmacovigilance study based on the FDA Adverse Event Reporting System (FAERS) from 2004 to 2022
    Du, Yikuan
    Zhu, Jinfeng
    Guo, Zhuoming
    Wang, Zhenjie
    Wang, Yuni
    Hu, Mianda
    Zhang, Lingzhi
    Yang, Yurong
    Wang, Jinjin
    Huang, Yixing
    Huang, Peiying
    Chen, Mianhai
    Chen, Bo
    Yang, Chun
    [J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2024, 17 (02) : 189 - 201
  • [30] Vedolizumab Adverse Events: Analysis of the FDA Adverse Event Reporting System
    Jow, Steven
    Hutfless, Susan
    [J]. INFLAMMATORY BOWEL DISEASES, 2017, 23 : S35 - S36
12345